Articles tagged with Cancer Patients
A study of 103,000 early-stage breast cancer patients reveals a significant racial disparity in chemosensitivity and survival rates. Black patients are more likely to experience residual disease after neoadjuvant chemotherapy, leading to a higher mortality risk.
A new study found that most people with colorectal cancer in sub-Saharan Africa receive inadequate treatment, leading to significantly improved life expectancy through simple measures. The mortality rate is up to 3.5 times higher in regions studied compared to countries with medium HDI scores.
A Phase II clinical trial has shown a clear clinical benefit of combining Dabrafenib and Trametinib in treating BRAF mutated low-grade paediatric gliomas. The combination therapy improved overall response rate by over four-fold and increased median progression-free survival.
A phase 2 trial found that durvalumab is safe and may benefit overall survival in non-small cell lung cancer patients with borderline performance status. The study also showed stable quality of life and a lower incidence of severe treatment-related adverse events compared to platinum doublet chemotherapy.
A UCLA study found that hospitals with high patient diversity are less likely to offer core cancer services, including hospice care, chemotherapy, and robotic surgery. The lack of these resources can impact treatment quality and outcomes for patients diagnosed with cancer.
Researchers developed an AI model using epigenetic factors to predict patient outcomes across multiple cancer types. The model successfully divided patients into two groups with different survival chances, and its genes were found to have a significant overlap with cluster-defining signature genes.
Elea Abisamra's STEM writing program at Virginia Tech has been recognized by the journal Cell for its innovative approach to teaching science through storytelling. The program has already helped 95 kids publish books with over 150 tutors as editors, and plans to expand globally.
A study published in PLOS ONE found that 35% of women with breast cancer used self-discovered or peer-recommended techniques to enhance their sexual function. These techniques fell into four main domains: pain reduction, intimacy and relationship enhancement, desire and arousal enhancement, and emotional coping.
A new ASTRO clinical guideline recommends partial breast irradiation as a viable alternative to whole breast radiation for patients with early-stage invasive breast cancer or DCIS, based on evidence from large randomized trials. The guideline provides guidance on patient selection and best practices for delivering effective partial bre...
A new AI method combines satellite imaging and ecological analysis techniques to interpret large amounts of data from tumor tissue, providing insights into how cancer works. This approach aims to tailor cancer treatments to individual needs and avoid unnecessary side effects.
The Max Foundation has started treating three patients with advanced breast cancer, including a CDK4/6 inhibitor therapy, in Mozambique. This marks the first time this treatment is available in low-income countries and aims to improve outcomes for women living with advanced breast cancer.
Experts call for urgent measures to address discrimination against patients fleeing war or conflict zones, those with serious mental illnesses, and frail elderly patients. Guidelines for treating advanced breast cancer should prioritize patient preferences and involve multidisciplinary care teams.
A study of 3.5 million patients diagnosed with cancer found a deficit in cancer treatments during the first year of the pandemic. The data showed decreases in cancer diagnoses but not changes in treatment strategies, highlighting the impact of the pandemic on cancer care.
Patients with breast cancer in conflict zones face significant barriers to treatment, including lack of standard procedures and funding for rebuilding capacity. This results in many patients being diagnosed with advanced breast cancer, often with limited palliative care options.
A Mayo Clinic study found patients with lower extremity lymphedema had twice the risk of developing skin cancer, including basal cell carcinomas and squamous cell carcinomas. Regular skin cancer screenings are crucial for these patients as early detection is critical.
A multinational study of almost one million individuals found a strong association between exposure to radiation from CT scans in young people and an increased risk of blood cancers. The study confirms that the benefits of computed tomography outweigh the risks, but emphasizes the need for strict radiological protection measures, parti...
Patients with HER2-positive breast cancer that has spread to other parts of the body survive for longer if treated with pyrotinib. The new drug targets proteins involved in HER2-positive breast cancer and shows a 22% reduction in risk of death compared to lapatinib.
A new study suggests that analyzing genetic material from nearby healthy tissue may help predict lung cancer's return after treatment. The study analyzed RNA from tumor cells and adjacent, seemingly normal lung tissue and found that the expression of genes associated with inflammation was especially useful for making predictions.
Researchers at UCLA have developed a new method to engineer more powerful immune cells that can potentially be used for 'off-the-shelf' cell therapy to treat challenging cancers. Gamma delta T cells with high expressions of CD16 surface marker exhibited increased ability to recognize and kill cancer cells.
Researchers at the University of Leicester have received a significant financial boost to advance their cancer treatment research. The team will investigate 'liquid biopsies' to reveal vital clues about cancer genetic makeup, aiming to predict how cancer changes and which treatment works best for individual patients.
A new study reveals a link between the removal of the FGFR1 protein's extracellular domain and a significant decrease in tumour volume. This finding offers a potential new avenue of treatment for patients with squamous cell carcinoma of the lungs, who have shown limited success with current therapies.
A large-scale study found that low-dose CT screening increases the 20-year survival rate of lung cancer patients from 18.6% to 81%, with Stage I cancers having an even higher long-term survival rate of 95%. Early detection through annual screening can effectively cure lung cancer in the long term.
New research suggests that vitamin D supplements can reduce the risk of peripheral neuropathy in patients undergoing paclitaxel treatment. The study found that patients with vitamin D deficiency were more likely to experience severe neuropathy, and that inducing vitamin D deficiency caused similar symptoms in a mice model study.
A study published in Oncotarget reveals that HER2 mutant alleles play a crucial role in determining treatment response to neratinib and poziotinib. Researchers found that individual HER2 mutant alleles have distinct effects on therapeutic efficacy, suggesting new targets for breast cancer therapy.
Researchers describe the use of ripretinib and repeated surgical resection in a patient with recurrent GIST harboring a KIT exon 11 mutation. The treatment led to extended clinical benefit, outperforming current reported data from ripretinib clinical trials.
A phase 1 trial of the radiopharmaceutical 225AC-J591 demonstrated promising antitumor activity against advanced metastatic prostate cancer, reducing PSA levels by at least half for 47% of patients. The treatment was well-tolerated, with only temporary low blood cell count side effects.
Bioethics researchers at Dana-Farber Cancer Institute warn that patient-facing AI can depersonalize care and erode relationships between patients and caregivers. The authors advocate for principles such as human dignity, patient autonomy, and regulatory oversight to ensure AI-driven healthcare is ethically sound and equitable.
Researchers have discovered a novel biomarker that enables the evaluation of near-infrared photoimmunotherapy (NIR-PIT) treatment success. The biomarker uses microbubbles to track tumor vessels and measure the effectiveness of NIR-PIT, which combines antibodies and near-infrared light to destroy cancer cells.
A UCLA-led study shows datopotamab deruxtecan, a Trop-2 directed antibody-drug conjugate, significantly improves progression-free survival in patients with metastatic non-small cell lung cancer. The treatment primarily benefits patients with non-squamous tumors, reducing disease progression and improving overall survival.
A study of 9,479 participants identified racial and ethnic disparities in breast cancer survival, highlighting the need for targeted interventions to improve outcomes for at-risk subgroups. The findings suggest that focused care approaches can address these disparities and promote more equitable treatment.
A clinical trial in Spain found that only 1 in 3 family members of patients with colorectal cancer participate in screening, missing opportunities for early detection. The study used fecal testing and colonoscopy to screen first-degree relatives, but uptake was low.
A clinical trial shows that a combination of atezolizumab and bevacizumab can reduce cancer recurrence in liver cancer patients by one-third after curative-intent resection or ablation. The therapy has improved recurrence-free survival rates compared to active surveillance, offering new hope for these patients.
A study published in CANCER reveals that individuals with diabetes, especially those with diabetic complications, have a higher risk of dying early from colorectal cancer. Patients with complicated diabetes had an 85% higher odds of death from any cause and 41% higher odds of death from cancer.
Researchers saw a major pathologic response in over half of surgical specimens from patients treated with neoadjuvant pembrolizumab. The treatment shrank over half of advanced melanomas, according to exploratory analyses presented at the European Society of Medical Oncology (ESMO) Congress 2023.
A clinical trial has shown that combining chemotherapy with immunotherapy nivolumab significantly improved outcomes in patients with advanced bladder cancer. The study found nearly twice as many patients with no evidence of disease after treatment, and a median complete response of 37.1 months.
A new drug, cabozantinib, has shown positive results in a clinical trial involving patients with advanced neuroendocrine tumors. The study found that patients treated with cabozantinib survived significantly longer without their disease worsening compared to those who received a placebo. This novel treatment strategy targets angiogenes...
A phase III pivotal trial evaluating cabozantinib in advanced neuroendocrine tumors demonstrated significant improvements in median progression-free survival (PFS) compared to placebo. The study met its primary objective for both cohorts of patients, providing encouraging news for those with progressive disease.
A phase 3 clinical trial found belzutifan significantly reduces the risk of progression in patients with metastatic clear cell renal cell carcinoma who had previously treated with immune checkpoint inhibitors and anti-angiogenic therapies. The drug demonstrated improved progression-free survival, higher overall response rates, and redu...
A secondary analysis of the SWOG S0931 trial found that patients with very-high risk clear-cell renal cell carcinoma who received adjuvant everolimus after surgery had a statistically significant improvement in recurrence-free survival. The results suggest that everolimus may be beneficial for this high-risk patient population, but als...
Researchers found that tumour cells escape immunotherapy by losing or changing BCMA and GPRC5D targets on their surface. This understanding has led to the suggestion of periodically profiling myeloma cells throughout a patient's treatment course to adapt treatment strategies.
Researchers found that online educational materials about breast surgery have a negative tone, exceed recommended reading levels, and are of poor quality. Studies assessed readability, bias, quality, and tone using validated tools, highlighting the need for accessible materials.
A new AI-based tool estimates patient-specific cancer survival rates using machine learning, offering personalized prognosis for patients with breast, thyroid, and pancreatic cancers. The Cancer Survival Calculator differs from existing estimators by incorporating multiple factors beyond disease stage.
Researchers are testing a single target to weaken tumors and strengthen immune cells in pediatric brain tumor patients. The goal is to improve the effectiveness of CAR-T therapy, which has shown promise but also leads to exhaustion of immune cells.
A new study found that ide-cel, a CAR T-cell therapy, showed similar survival outcomes for Black and white patients with multiple myeloma. Researchers hope this finding encourages the use of ide-cel in all patients with multiple myeloma.
Researchers discovered that lactate-producing intratumoral bacteria drives resistance to radiation therapy. Cancer cells respond to radiation by rewiring metabolic signaling pathways using lactic acid instead of glucose.
A study by researchers at Keck School of Medicine of USC found that Black cancer survivors experience slowdowns in diagnosis and delivery of care due to exposure to racial discrimination. Positive interactions, such as ready access to providers and displays of empathy, were identified as key factors in improving care.
A simple MRI scan and a new metric for prostatic urethra length may help identify men at risk of chronic urinary side effects after radiation therapy. The study found that longer prostatic urethras are associated with a higher likelihood of these symptoms, which can impact quality of life.
In a phase I trial, an oncolytic virus treatment designed by Brigham researchers extended survival among patients with recurrent glioblastoma, especially those with pre-existing viral antibodies. The therapy reshaped the tumor's surrounding environment to stimulate an anti-tumor immune response.
Dana-Farber Cancer Institute presents several studies on novel treatments, combination therapies, and personalized medicine for lung, kidney, and neuroendocrine tumors. The studies include pivotal trials on adagrasib with pembrolizumab for non-small cell lung cancer and belzutifan versus everolimus for clear cell renal cell carcinoma.
Researchers will study the impact of exercise, intermittent fasting, and their combination on fatigue, biomarkers of inflammation, and quality of life in women with advanced breast cancer. The trial aims to improve treatment tolerability and possibly life duration for these patients.
A team of researchers has developed a new visualization tool combining high-speed cameras and fluorescent injection to distinguish tumor tissue from normal tissue across cancer types. The technique, known as fluorescence lifetime (FLT) imaging, achieved an accuracy of over 97% in distinguishing tumor tissue from healthy tissue.
A Rutgers study examines how oncology doctors facilitate psychological well-being, finding that providers who show more empathy promote better psychological health among breast cancer patients. The research also highlights the importance of addressing uncertainty throughout the cancer trajectory to facilitate psychological adjustment.
A new study published in JNCCN found that intensive local-regional treatment to remove as much tumor as possible did not significantly impact overall quality of life for patients with metastatic colorectal cancer. However, the treatment was associated with a higher risk of adverse events.
A multilevel primary care intervention, including electronic health record reminders and patient outreach, improved timely follow-up of overdue abnormal cancer screening test results for breast, cervical, colorectal, and lung cancer. The intervention was found to be effective in reducing missed screenings.
A new blood test called OvaPrint TM detects specific nucleic acids in the blood, distinguishing between cancerous and benign pelvic masses with high accuracy. The test has the potential to improve treatment outcomes by identifying the best surgical approach for patients with a pelvic mass.
The study developed a highly accurate AI model for fully automated cancer detection, including small and difficult-to-detect tumors. The model could detect visually imperceptible cancer from normal-appearing pancreases substantially early before clinical diagnosis, with a median of 438 days.
A phase 2 clinical trial found that serial blood tests can identify patients who benefit from additional immunotherapies, suggesting a potential early marker of treatment response. The study also showed that ctDNA analyses correlated with tumor size and survival, making it a promising strategy for guiding therapy.
Researchers discuss lurbinectedin as a method to treat neuroendocrine tumors (NETs), with encouraging results from phase II basket studies demonstrating activity in platinum-sensitive relapsed SCLC and other malignancies. Lurbinectedin's mechanism of action involves inhibiting oncogenic transcription, promoting apoptosis and cell death.
Researchers identified a circulating tumor DNA (ctDNA) biomarker that can predict disease recurrence and response to treatment in patients with BRAF-negative melanoma. The study found that measuring ctDNA levels and variants can help tailor therapy and improve patient outcomes.
A team of researchers at Mays Cancer Center has identified protein markers that could signal the early development of metastatic lung cancer. These markers have led to a $1.6 million grant and will pave the way for a clinical trial in patients with advanced lung cancer.